Beneficial effects of iron therapy in renal failure patients on hemodialysis

Kidney International, Supplement

Volumn 55, Issue 69, 1999, Pages

  Fishbane, Steven ^a,b   Mittal, Sanjeev K ^a   Maesaka, John K ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Anemia; Dialysis; Erythropoietin; Iron replacement

Indexed keywords

FERRIC GLUCONATE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; IRON; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; FERRITIN; TRANSFERRIN;

ANEMIA; DRUG COST; DRUG FORMULATION; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; BLOOD; CHRONIC KIDNEY FAILURE; IRON INTAKE; METABOLISM; RENAL REPLACEMENT THERAPY;

ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; IRON, DIETARY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TRANSFERRIN;

EID: 0032911837     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.055suppl.69067.x     Document Type: Review

References (34)

1. POWE NR, GRIFFTTHS RI, GREER JW, WATSON AJ, ANDERSON GF, DE LISSOVOY G, HERBERT RJ, EGGERS PW, MILAM RA, WHELTON PK: Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 43:1125-1133, 1993
2. YOUNG EW, BLOEMBERGEN WE, WOODS JD, EMMERT G, PORT FK, WOLFE RA, JONES CA, HELD PJ: Iron use among erythropoietin treated US hemodialysis patients (abstract). J Am Soc Nephrol 7:1469, 1996
3. VAN WYCK DB, STIVELMAN JC, RUIZ J, KIRLIN LF, KATZ MA, OGDEN DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
4. CAVILL I, MACDOUGALL IC: Erythropoiesis and iron supply in patients treated with erythropoietin. Erythropoiesis 3:50-55, 1992
5. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987
6. BRUGNARA C, COLLELA GM, CREMINS J, LANGLEY RC JR, SCHNEIDER TJ, RUTHERFORD CJ, GOLDBERG MA: Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 123:660-667, 1994
7. FAIRBANKS VF, BEUTLER E: Iron metabolism, in Williams Hematology (5th ed). New York, McGraw-Hill Inc., 1995, pp 369-380
8. MACDOUGALL IC, ROBERTS DE, NEUBERT P, DHARMASENA AD, COLES GA, WILLIAMS JD: Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant human erythropoietin in patients on CAPD. Contr Nephrol 76:112-121, 1989
9. HALLBERG L: Bioavailability of dietary iron in man. Annu Rev Nutr 1:123-147, 1981
10. KOOISTRA MP, VAN ES A, STRUYVENBERG A, MARX JJM: Low iron absorption in erythropoietin-treated hemodialysis patients. (abstract) J Am Soc Nephrol 6:543, 1995
11. DONNELLY SM, POSEN GA, ALI MA: Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14:271-276, 1991
12. ESCHBACH JW, COOK JD, FINCH CA: Iron absorption in chronic renal disease. Clin Sci 38:191-196, 1970
13. SCHNEIDER W: The fate of iron compounds in the gastrointestinal tract. Arzneimittelforschung 37:92-95, 1987
14. HALLBERG L, RYTTINGER L, SOLVELL L: Side effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 459:3-10, 1966
15. WINGARD RL, PARKER RA, ISMAIL N, HAKIM RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995
16. KAMAKAKOM K, CAVILL I, JACOBS A: The metabolism of intravenously administered iron dextran. Br J Haematol 25:637-643, 1973
17. WOOD JK, MILNER PFA, PATHAK UN: The metabolism of iron-dextran given as a total dose infusion to iron deficient Jamaican subjects. Br J Haematol 14:119-129, 1968
18. VERCAMMEN M, GOEDHUYS W, BOEYCKENS A, DE ROY R, SENNESAEL J, SEVENS S, GORUS F: Iron and total iron binding capacity in serum of patients receiving iron-dextran: Kodak Ektachem methodologies, spectrophotometry, and atom absorption spectrometry compared. Clin Chem 36:1812-1815, 1990
19. FISHBANE S, LYNN RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44:238-240, 1995
20. SUNDER-PLASSMAN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
21. MACDOUGALL IC, TUCKER B, THOMPSON J, BAKER LRI, RAINE AEG: A randomised controlled study of iron supplementation in patients treated with erythropoietin. (abstract) J Am Soc Nephrol 4:428, 1993
22. FISHBANE S, FREI GL, MAESAKA J: Reduction of recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
23. SENGER JM, WEISS RJ: Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 23:319-323, 1996
24. SCHAEFER RM, SCHAEFER L: Management of iron substitution during rHuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75, 1992
25. TAYLOR JE, PEAT N, PORTER C, MORGAN AG: Regular low dose intravenous iron therapy improves response to erythropoietin in bemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996
26. SEPANDJ F, JINDAL K, WEST M, HIRSCH D: Economic appraisal of maintenance parenteral iron administration in treatment of the anemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996
27. HAMSTRA RD, BLOCK MH, SCHOCKET AL: Intravenous iron dextran in clinical medicine. JAMA 243:1726-1731, 1980
28. FISHBANE S, UNGUREANU VD, MAESAKA JK, ADAM G, KAUPKE CJ, LIM V, WISH J: A multicenter study of the safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:528-534, 1996
29. NISSENSON AR, LINDSAY RM, SWAN S, LAMBRECHT LL, SELIGMAN P: Ferric gluconate is safe and effective in hemodialysis patients: North American Trial. (abstract) J Am Soc Nephrol 7:1459, 1996
30. NISSENSON AR, SWAN S, LAMBRECHT LL, ANDERSON P, SCHWEITZER S: Ferrix gluconate is safe in hemodialysis patients who react to iron dextran. J Am Soc Nephrol 7:1460, 1996
31. GEISSER P, BAER M, SCHAUB E: Structure/histiotoxicity relationships of parenteral iron preparations. Arzneimittelforschung 42: 1439-1452, 1992
32. ZANEN AL, ADRIAANSEN HJ, VAN BOMMEL EFH, POSTHUMA R, DE JONG GMTH: Oversaturation of transferrin after intravenous ferric gluconate in haemodialysis patients. Nephrol Dial Transplant 11:820-824, 1996
33. AUERBACH M, WINCHESTER J, WAHAB A, RICHARDS K, McGINLEY M, HALL F, ANDERSON J, BRIEFEL G: A randomized trial of three iron dextran infusion methods for anemia of erythropoietin treated dialysis patients. Am J Kidney Dis 31:81-86, 1998
34. NKF-DOQI Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30:192-240, 1997